Skip to main content

In relapsing MS, Mavenclad users' thinking scores rose

By MS Buddy ·

Summarized from European neurology, Nov 2026 · PubMed. AI-generated summary. Not medical advice.

Observational study · 173 people with MS who received Mavenclad

Research by Serkan Ozakbas, Ela Simay Zengin and 3 colleagues.

How did thinking and walking change for people with MS taking Mavenclad?

Key Takeaway

Among people with relapsing MS taking Mavenclad, thinking test scores improved, while a timed walking test took longer.

Brain outline filled with fine, branching nerve fibers on an off-white background.
Credibility
Interest
Share:1 min read

What They Found

Researchers followed 173 people with MS after they started cladribine (Mavenclad). Over two years, about 95% had no relapses. Brain scans showed no new signs of disease activity in about 97%. In a smaller group, scores improved on every thinking test used. Timed walking took longer over time, while results on a hand movement test did not change clearly.

Who Should Care and Why

This study followed people with MS who received Mavenclad, a drug used for relapsing MS. It looked at relapses and brain scans over two years. A smaller group also took thinking and movement tests. The thinking results may interest people concerned about changes in memory or focus. The walking results show that not every measure improved during follow-up.

Important Considerations

If you take Mavenclad, these results come from a review of records for 173 people, not a trial comparing treatments. The abstract does not say how many people took the thinking and movement tests. Without a comparison group, the study cannot show that Mavenclad caused the changes.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in European neurology by et al.. Reproduced from the PubMed record.

Cladribine tablets are an established oral immune reconstitution therapy for relapsing multiple sclerosis, with proven clinical and radiological efficacy. However, evidence regarding their effects on cognitive and physical outcomes in real-world settings remains limited. To assess the clinical, radiological, cognitive, and physical outcomes of cladribine treatment in people with Multiple Sclerosis (pwMS) over a follow-up of up to two years in a real-world cohort. A total of 173 patients with multiple sclerosis (pwMS) received cladribine treatment and were subsequently followed over time. Clinical data, including relapse rate, EDSS, and MRI findings, were collected annually. Cognitive (BICAMS: Brief International Cognitive Assessment for MS) and physical performance (T25FW: Timed-25-Foot Walking Test, N-HPT: Nine-Hole Peg Test) data of a subgroup of participants were collected at baseline, year 1, and year 2. The mean age was 36.75 ± 11.44, and the mean disease duration was 8.33 ± 6.85 years. Over a two-year follow-up, 94.8% of patients remained relapse-free, and MRI activity was absent in 96.5%. Significant improvements were observed in all BICAMS subtests (p < 0.05). While T25FW increased over years (p: 0.017), NHPT showed a similar trajectory (p>0.05). Cladribine demonstrated high efficacy in suppressing clinical and radiological activity while supporting cognitive stability.

Trials you could look into

This study looked at a treatment with MS trials currently recruiting or under way.

Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

A winding blue paper path curves around ochre shapes toward a resting circle bordered by an incomplete paper ring.
MS fatigue may reflect extra effort to control movement

11/17/2026

A review suggests MS fatigue may reflect extra effort to control movement and incomplete recovery af

Read More
Two paper patchwork circles have similar overall colors but different pieces, with folds hiding or revealing layers.
Computer studies show MS fatigue surveys differ by person

11/16/2026

Computer studies found MS fatigue surveys can give similar group results but different individual sc

Read More
Three soft ribbons in muted clay, sage and blue follow varied, loosely overlapping paths on an off-white background.
Exercise and coping programs helped fatigue in MS review

11/17/2026

A review found exercise, therapy focused on thoughts and behavior, and self-management programs show

Read More
Navy nerve-like lines meet at a central junction, with gaps in their ochre protective sleeves.
MS tissue and mice show damage in a brain vision hub

11/17/2026

Donated MS brain tissue showed damage in a vision hub. Mouse findings linked local immune cell activ

Read More
A blue brain outline beside two loosely intertwined blue and ochre paths with varying space between them.
Thinking problems linked to sexual difficulties in MS

1/1/2026

A study of 318 people with MS linked lower thinking test scores to more sexual difficulties, with th

Read More
Two parallel paths: one grows uneven while speech-wave shapes beside it become shorter and fainter.
Voice problems were greater with more disability in MS

11/14/2026

In a study of people with MS, those with greater disability reported more voice problems and vocal f

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.